Bortezomib and restoration of chemosensitivity.
Gozzetti
Alessandro
A
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008081:Liposomes / Q000737:chemistry; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D011092:Polyethylene Glycols / Q000737:chemistry; D011719:Pyrazines / Q000008:administration & dosage*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D008081:Liposomes; D011719:Pyrazines; D011092:Polyethylene Glycols; D000069286:Bortezomib; D004317:Doxorubicin